News
Recent news about Panacea Capital and select portfolio companies
April 17, 2026
From China, Bridging Biopharmaceutical Innovation in Korea - Chime Biologics Empowers a New Landscape for Korea's Biopharma Industry
April 17, 2026
From China, Bridging Biopharmaceutical Innovation in Korea - Chime Biologics Empowers a New Landscape for Korea's Biopharma Industry
April 9, 2026
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
April 9, 2026
Kainova Therapeutics Expands Phase I / II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
April 3, 2026
Winning in Biosimilars: Speed, Scale, and the New Competitive Playbook
April 3, 2026
Winning in Biosimilars: Speed, Scale, and the New Competitive Playbook
March 27, 2026
Chime Biologics Congratulates Hope Medicine Inc. on Successful Dosing of First Patient in Phase III Clinical Trial for Endometriosis in China
March 27, 2026
Chime Biologics Congratulates Hope Medicine Inc. on Successful Dosing of First Patient in Phase III Clinical Trial for Endometriosis in China
March 26, 2026
pharmaphorum – BIO‑Europe Spring 2026: In conversation with Marjorie Sidhoum, Vice President of Business Development and Corporate Communications at Kainova Therapeutics
March 26, 2026